Infliximab eye drops treatment in corneal neovascularization • JML Journal of Medicine and Life

2015, Volume 8, Issue 4, pp 566 – 567

Infliximab eye drops treatment in corneal neovascularization

Issues

Special Issues

Authors and Affiliations

Voiculescu OB ^*

Voinea LM ^**

* *Department of Cellular and Molecular Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

** **Department of Ophthalmology, University Emergency Hospital Bucharest, Romania

Correspondence to: Olivia-Beatrice Voiculescu, MD, PhD student Department of Cellular and Molecular Medicine, “Carol Davila” University of Medicine and Pharmacy, 8 Eroilor Sanitari Bld., Code 050474, District 5, Bucharest, Romania Mobile phone: +40728 899 320, E-mail: biajeleut@yahoo.com

Abstract

Corneal neovascularization is a serious condition that may arise secondary to chemical burns, ischemia, infection, trauma, and inflammation and represents a major cause of blindness. This study investigated the efficacy of topical application of infliximab [tumor necrosis factor-a (TNF-a) monoclonal antibody] in the treatment of corneal neovascularization in the rabbit model.

Keywords

neovascularizationantiVEGF agents

Preview

JMedLife-08-566

Download PDF

About this article

PMC ID: 4656973
PubMed ID: 26664491
DOI:

Article Publishing Date (print): Oct-Dec 2015
Available Online:

Journal information

ISSN Printing: 1844-122X
ISSN Online: 1844-3117
Journal Title: Journal of Medicine and Life

Copyright License: Open Access

This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.